This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Intranodal neoantigen DC vaccination showed clinical responses in some advanced cancer patients, with response dependent on immune activation rather than neoantigen number.
Why it matters
Personalized cancer vaccines could help patients who have run out of other options. Intranodal delivery may improve immune responses.
The numbers in context
N=17; intranodal ultrasound-guided injection; ELISpot monitoring; response dependent on immune activation, not neoantigen number
How the study worked
Retrospective analysis of 17 patients with treatment-resistant advanced cancers. Whole exome sequencing for neoantigen prediction. Peptide-pulsed autologous DCs injected into lymph nodes via ultrasound. ELISpot immune monitoring.
Who was studied
17 patients with treatment-resistant advanced solid tumors
What this study cannot tell us
Retrospective analysis. Small sample (N=17). No control group. Heterogeneous cancer types. Not all patients responded.
Read the original research
Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis.
Anticancer research, 41(8), 4101-4115
Citation
Morisaki, Takashi; Morisaki, Takafumi; Kubo, Makoto; Onishi, Hideya; Hirano, Tatsuya; Morisaki, Shinji; Eto, Masatoshi; Monji, Keisuke; Takeuchi, Ario; Nakagawa, Shinichiro; Tanaka, Hiroto; Koya, Norihiro; Umebayashi, Masayo; Tsujimura, Kenta; Yew, Poh Yin; Yoshimura, Sachiko; Kiyotani, Kazuma; Nakamura, Yusuke. (2021). Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis.. Anticancer research, 41(8), 4101-4115. https://doi.org/10.21873/anticanres.15213